

Revision date: 17-Apr-2018 Version: 4.1 Page 1 of 8

# **IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING**

**Product Identifier** 

Material Name: Celecoxib

**Trade Name:** Not applicable **Compound Number:** SC-58635

YM-177, CJ-016377, CP-598107, PF-00345549, PHA-00846533 Synonyms:

**Chemical Family:** COX-2 inhibitor

**CAS Number** 169590-42-5

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical active

Details of the Supplier of the Safety Data Sheet

**Pfizer Global Supply** Pfizer Ltd Pfizer Inc Ramsgate Road 235 East 42nd Street Sandwich, Kent New York, NY 10017 **CT13 9NJ** 1-800-879-3477 **United Kingdom** +00 44 (0)1304 616161

**Emergency telephone number: Emergency telephone number:** 

CHEMTREC (24 hours): 1-800-424-9300 ChemSafe (24 hours): +44 (0)208 762 8322

Contact E-Mail: pfizer-MSDS@pfizer.com

# **HAZARDS IDENTIFICATION**

### Classification of the Substance or Mixture

**GHS - Classification** 

Reproductive Toxicity: Category 1B

Specific target organ systemic toxicity (repeated exposure): Category 2

Chronic aquatic toxicity: Category 1

**US OSHA Specific - Classification** 

**Physical Hazard:** Combustible Dust

**Label Elements** 

Signal Word: Danger

**Hazard Statements:** H360D - May damage the unborn child

H373 - May cause damage to organs through prolonged or repeated exposure if swallowed

H410 - Very toxic to aquatic life with long lasting effects

May form combustible dust concentrations in air

Material Name: Celecoxib

Revision date: 17-Apr-2018

Page 2 of 8

Version: 4.1

\_\_\_\_\_

**Precautionary Statements:** P201 - Obtain special instructions before use

P202 - Do not handle until all safety precautions have been read and understood

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P260 - Do not breathe dust/fume/gas/mist/vapors/spray P314 - Get medical attention/advice if you feel unwell

P405 - Store locked up P391 - Collect spillage

P273 - Avoid release to the environment

P501 - Dispose of contents/container in accordance with all local and national regulations



Other Hazards

An Occupational Exposure Value has been established for this substance ( see Section 8 ).

Note:

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

# 3. COMPOSITION / INFORMATION ON INGREDIENTS

### Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Celecoxib	169590-42-5	Not Listed	STOT RE 2 (H373) Aquatic Chronic 1 (H410) Repr. 1B (H360D)	100

Additional Information: Ingredie

Ingredient(s) indicated as hazardous have been assessed under standards for workplace

safety.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

# 4. FIRST AID MEASURES

**Description of First Aid Measures** 

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention

immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek

medical attention.

**Ingestion:** Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Material Name: Celecoxib

Revision date: 17-Apr-2018

Version: 4.1

\_\_\_\_\_

### Most Important Symptoms and Effects, Both Acute and Delayed

**Symptoms and Effects of** For information on potential signs and symptoms of exposure, See Section 2 - Hazards

**Exposure:** Identification and/or Section 11 - Toxicological Information.

Medical Conditions None known

Aggravated by Exposure:

#### Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

### 5. FIRE FIGHTING MEASURES

**Extinguishing Media:** Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion May include oxides of nitro

Products:

May include oxides of nitrogen, sulfur, carbon. May include products of fluorine.

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

#### **Advice for Fire-Fighters**

During all firefighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

#### 6. ACCIDENTAL RELEASE MEASURES

#### Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

#### **Environmental Precautions**

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

#### Methods and Material for Containment and Cleaning Up

Measures for Cleaning /

Collecting:

Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of

dry solids. Clean spill area thoroughly.

**Additional Consideration for** 

Large Spills:

Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Cleanup operations should only be undertaken by trained personnel.

### 7. HANDLING AND STORAGE

#### **Precautions for Safe Handling**

Ground and bond all bulk transfer equipment. Avoid open handling. Minimize dust generation. Use local exhaust ventilation or perform work under fume hood/fume cupboard. Avoid inhalation and contact with skin, eye, and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Refer to Section 12 - Ecological Information, for information on potential effects on the environment. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

### Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store at room temperature in properly labeled containers. Keep away from heat, sparks and

flames.

**Specific end use(s):** Pharmaceutical active

\_\_\_\_\_

**Material Name: Celecoxib** Page 4 of 8 Revision date: 17-Apr-2018 Version: 4.1

## 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**Control Parameters** 

Celecoxib

1000µg/m<sup>3</sup> Pfizer OEL TWA-8 Hr:

**Exposure Controls** 

Eves:

Engineering controls should be used as the primary means to control exposures. Use process **Engineering Controls:** 

containment, local exhaust ventilation, or other engineering controls to maintain airborne levels

below recommended exposure limits.

**Personal Protective** 

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE). Contact your safety and health professional or safety equipment **Equipment:** 

supplier for assistance in selecting the correct protective clothing/equipment based on an assessment of the workplace conditions, other chemicals used or present in the workplace and

specific operational processes.

Hands: Wear impervious gloves (e.g. Nitrile, etc.) as minimum protection. (Protective gloves must

> meet the standards in accordance with EN374, ASTM F1001 or international equivalent.) Wear safety glasses as minimum protection. (Safety glasses must meet the standards in

accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Wear impervious protective clothing when handling this compound. (Protective clothing must

meet the standards in accordance with EN13982, ANSI 103 or international equivalent.)

Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is Respiratory protection:

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

equivalent.)

# 9. PHYSICAL AND CHEMICAL PROPERTIES

**Physical State:** Solid Color: White

Odor: No data available. **Odor Threshold:** No data available.

Molecular Formula: C17H14F3N3O2S **Molecular Weight:** 381.38

Soluble: Acetone, Ethanol, Dimethylsulfoxide, Ethyl acetate **Solvent Solubility:** 

Water Solubility: 5.0 mg/L (20 °C) No data available. pH:

pKa: 11.1 **Melting/Freezing Point (°C):** 156-157

**Boiling Point (°C):** No data available. Partition Coefficient: (Method, pH, Endpoint, Value)

Celecoxib

Measured Log P 3.53

**Decomposition Temperature (°C):** No data available.

**Evaporation Rate (Gram/s):** No data available Vapor Pressure (kPa): No data available Vapor Density (g/ml): No data available **Relative Density:** No data available

Particle Size (um): 4.0

Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available Flammability (Solids): No data available

SC-58635

Material Name: Celecoxib

Revision date: 17-Apr-2018

Version: 4.1

Flash Point (Liquid) (°C):

Upper Explosive Limits (Liquid) (% by Vol.):

No data available
No data available
No data available
No data available

**Dust Explosivity:** 

Min. Ignition Energy (mJ): 100-300

**Electrostatic Risk:** 

Resistivity (ohm-m):

Powder: Ambient: > 4e13 Low: > 4e13

### 10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable at normal conditions

**Possibility of Hazardous Reactions** 

Oxidizing Properties: No data available

**Conditions to Avoid:** Fine particles (such as dust and mists) may fuel fires/explosions. **Incompatible Materials:** As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition No data available

**Products:** 

### 11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

Short Term: Minimal eye irritant in experimental animals .

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on the

developing fetus. May have long-term effects on the aquatic environment.

Known Clinical Effects: Ingestion of this material may cause effects similar to those seen in clinical use including

gastrointestinal effects such as nausea, pain, heartburn, bleeding, ulceration, and perforation. Serious allergic reactions, including anaphylaxis, have been reported. Clinical use of this drug has caused swelling of face/extremities, headache, dizziness, insomnia, increase in blood pressure (hypertension), respiratory infection, heart attack (myocardial infarction), stroke, congestive heart failure, kidney effects, changes in blood cell levels, Stevens Johnson Syndrome (epidermal necrosis and exfoliative dermatitis). It may also cause prolonged

bleeding time.

#### Acute Toxicity: (Species, Route, End Point, Dose)

Celecoxib

Rat Oral LD 50 > 2000 mg/kg Dog Oral LD 50 > 2000mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable

at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Celecoxib

Skin Irritation Rabbit No effect Eye Irritation Rabbit Minimal

Skin Sensitization - GPMT Guinea Pig No effect

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Celecoxib

Material Name: Celecoxib Page 6 of 8 Revision date: 17-Apr-2018 Version: 4.1

### 11. TOXICOLOGICAL INFORMATION

13 Week(s)	Rat	Orai	20 mg/kg/day	NOAEL	Kidney, Gastrointestinai System
13 Week(s)	Dog	Oral	35 mg/kg/day	NOAEL	Gastrointestinal system
6 Month(s)	Rat	Oral	20 mg/kg/day	NOAEL	Gastrointestinal system, Kidney
12 Month(s)	Dog	Oral	35 mg/kg/day	NOAEL	Gastrointestinal system

### Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

#### Celecoxib

Embryo / Fetal Development	Rat Oral	50 mg/kg/day LOA	EL Fetotoxicity
Embryo / Fetal Development	Rabbit Oral	100 mg/kg/day	LOAEL Fetotoxicity
Embryo / Fetal Development	Rat Oral	30 mg/kg/day LOA	.EL Teratogenic
Embryo / Fetal Development	Rabbit Oral	60 mg/kg/day N	IOAEL Teratogenic

### Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

#### Celecoxib

**Bacterial Mutagenicity (Ames)** Salmonella Negative Mammalian Cell Mutagenicity **HGPRT** Negative Direct DNA Interaction Not applicable Negative

In Vitro Cytogenetics Chinese Hamster Ovary (CHO) cells Negative

In Vivo Micronucleus Not applicable Negative

### Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

#### Celecoxib

Oral 200 (M), 10 (F) mg/kg/day Not carcinogenic 2 Year(s) Rat NOAEL 2 Year(s) Mouse Oral 25 (M), 50 (F) mg/kg/day NOAEL Not carcinogenic

**Carcinogen Status:** Not listed as a carcinogen by IARC, NTP or US OSHA.

### 12. ECOLOGICAL INFORMATION

**Environmental Overview:** May have long-term effects on the aquatic environment. Releases to the environment should

be avoided. See aquatic toxicity data, below:

Toxicity:

### Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

#### Celecoxib

Daphnia magna (Water Flea) TAD 48 Hours EC50 > 1.5 mg/L

Pimephales promelas (Fathead Minnow) >1.2 mg/L TAD LC50 96 Hours Selenastrum capricornutum (Green Alga) TAD 12 Days 0.11 mg/L NOEC Microcystis aeruginosa (Blue-green Alga) **NOEC** TAD 14 Days 0.089 mg/L Ceriodaphnia dubia (Daphnids) NOEC 7 Days 0.17 mg/L TAD

Pimephales promelas (Fathead Minnow) OECD NOEC

33 Days 0.23 mg/L

Daphnia magna (Water Flea) FPA NOEC 21 Days 0.06 mg/L

A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum **Aquatic Toxicity Comments:** 

solubility. Since the substance is insoluble in aqueous solutions above this concentration, an

acute ecotoxicity value (i.e. LC/EC50) is not achievable.

SC-58635

Material Name: Celecoxib

Revision date: 17-Apr-2018

Version: 4.1

\_\_\_\_\_

Bacterial Inhibition: (Inoculum, Method, End Point, Result)

Celecoxib

Trichoderma viride (Fungus) TAD MIC > 1000 mg/L

Persistence and Degradability:

Biodegradation: (Method, Inoculum, Biodeg Study, Result, Endpoint, Duration, Classification)

Celecoxib Ready 53.2% After 28 Day(s) Not Ready

**Bio-accumulative Potential:** 

Partition Coefficient: (Method, pH, Endpoint, Value)

Celecoxib

Measured Log P 3.53

Mobility in Soil: No data available

### 13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental

releases. This may include destructive techniques for waste and wastewater.

### 14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

This material is regulated for transportation as a hazardous material/dangerous good.

UN number: UN 3077

**UN proper shipping name:** Environmentally Hazardous Substance, Solid, n.o.s (celecoxib)

Transport hazard class(es): 9
Packing group: 9

Environmental Hazard(s): Marine Pollutant

### 15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Celecoxib

Material Name: Celecoxib Page 8 of 8 Revision date: 17-Apr-2018 Version: 4.1

### 15. REGULATORY INFORMATION

**CERCLA/SARA 313 Emission reporting** Not Listed **California Proposition 65** Not Listed Standard for the Uniform Scheduling Schedule 4

for Drugs and Poisons:

**EU EINECS/ELINCS List** Not Listed

# 16. OTHER INFORMATION

### Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Specific target organ toxicity, repeated exposure-Cat.2; H373 - May cause damage to organs through prolonged or repeated exposure if swallowed

Hazardous to the aquatic environment, chronic toxicity-Cat.1; H410 - Very toxic to aquatic life with long lasting effects

**Data Sources:** Pfizer proprietary drug development information.

Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Reasons for Revision:

Updated Section 2 - Hazard Identification. Updated Section 8 - Exposure Controls / Personal

Protection.

**Revision date:** 17-Apr-2018

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

**End of Safety Data Sheet**